Latest Biotech News

ASGCT highlighted strategies to address AAV’s long-standing “one-and-done” limitation, focusing on redosing approaches and overcoming pre-existing immunity that can blunt subsequent...

enGene’s Phase II LEGEND interim updates for detalimogene voraplasmid delivered a deterioration versus earlier expectations, triggering a sharp investor selloff. The updated data showed complete...

AbCellera reported Phase 1 data for ABCL635, adding new evidence for the company’s pipeline momentum as it advances its antibody-development platform. While the excerpt does not provide outcome...

GSK took rights to a cardiovascular siRNA program from China-based SiranBio, targeting ALK7. The agreement covers most global rights but excludes mainland China, Hong Kong, Macau and Taiwan, where...

European regulators cleared Fractyl Health’s clinical test of a GLP-1 gene therapy, placing the company at the center of the race to deliver “one-and-done” alternatives to chronic GLP-1 injections...

Roche agreed to acquire PathAI in a deal valued at $750 million upfront, aiming to strengthen AI-powered digital pathology capabilities used by pathology labs and biopharma customers. The...

MBX Biosciences drew investor attention after preliminary Phase 1 data suggested efficacy and tolerability for its monthly obesity drug MBX-4291, a GLP-1/GIP co-agonist prodrug. The company...

Windward Bio secured $165 million for clinical trials targeting respiratory diseases, according to the company’s financing announcement. The round will support a lead program in respiratory...

Bristol Myers Squibb moved deeper into China’s oncology R&D ecosystem by signing a broad partnership with Hengrui Pharma, agreeing to pay $600 million upfront for 13 early-stage programs spanning...

Partner Therapeutics secured its first FDA approval with Bizengri, a bispecific antibody for advanced cholangiocarcinoma driven by NRG1 gene fusions. The approval adds a new targeted option for a...

Roche announced it will acquire PathAI in a deal valued at $750 million upfront, aiming to expand AI-powered digital pathology capabilities for pathology labs and biopharma development. PathAI’s...

enGene’s stock tumbled after updated Phase II LEGEND trial data for its nonviral gene therapy candidate detalimogene voraplasmid in high-risk BCG-unresponsive nonmuscle invasive bladder cancer....

ASGCT highlighted a core challenge for AAV gene therapy: redosing constraints driven by pre-existing immunity and immune responses that can limit future administrations. In a roundup of...

Bright Uro received FDA 510(k) clearance for the Glean abdominal sensor, expanding the Glean urodynamics system to support multichannel urodynamic studies. The sensor enables clinicians to capture...

GSK took rights to a cardiovascular siRNA program from China-based SiranBio, centered on ALK7 knockdown linked to reductions in visceral fat and cardiovascular risk markers. The agreement grants...

Windward Bio raised $165 million to support clinical testing of its respiratory antibody programs, positioning the company for trials in asthma, COPD, and related inflammatory indications. The...

Genewiz launched Gene Synthesis 2.0, upgrading how researchers design and order genes through a faster, packaged ordering experience and updated codon optimization. The platform includes Sprint,...

Nuclera introduced an antibody triage screening service designed to speed the transition from AI or in silico hit generation to lead selection and mammalian validation. The service screens large...

Partner Therapeutics’ Bizengri (bispecific antibody) became the first FDA-approved therapy for advanced cholangiocarcinoma driven by NRG1 gene fusions, marking a regulatory milestone for a...

Roche agreed to acquire PathAI in a deal valued at $750 million upfront, aiming to accelerate AI-powered digital pathology across pathology laboratories and biopharma workflows. The transaction...